[ad_1]
This dose is intended to provide enhanced immune protection to people who received the first two doses..
The two companies said: “Pfizer and Piontech noted that there are encouraging results from ongoing trials on a third dose of the current vaccine.” They added that they “are set to provide this data to the United States Food and Drug Administration, the European Medicines Agency and other regulatory authorities in the coming weeks.”“.
The two companies’ statement continued: “Preliminary study data shows that a dose of vaccination given 6 months after the second dose” provides “high levels of antibodies” to the virus, including against the mutant “beta. “, appeared in South Africa. . These levels are “5 to 10 times higher” than those seen after the first two doses..
The two companies have indicated that the results of this study will be published in a scientific journal..
They also pointed out that their vaccine had given good results in the laboratory against the “delta” mutant, and that a third dose would therefore also be able to strengthen the immunity against this mutant. They said tests were underway to “confirm this hypothesis.”
[ad_2]
Source link
